Gubra A/S — Investor Relations & Filings

Gubra A/S is a biotechnology company and preclinical Contract Research Organization (CRO) specializing in peptide-based drug discovery. The company operates a dual business model, providing preclinical research services to pharmaceutical and biotech clients while also developing its own proprietary pipeline of therapeutics. Gubra's primary focus is on metabolic diseases, such as obesity, diabetes, and MASH (metabolic dysfunction-associated steatohepatitis), as well as fibrotic diseases. Its research and development activities also extend into inflammatory conditions, CNS, respiratory, and women's health. The CRO services division supports clients in advancing their drug development programs through expertise in areas like in vivo pharmacology and peptide chemistry.